BACKGROUND: Pre-exposure prophylaxis (PrEP) use among populations most vulnerable to HIV as identified in the national HIV prevention goals is not fully known. This systematic review assessed trends of lifetime self-reported PrEP use and disparities among key populations. METHODS: We used the CDC HIV/AIDS Prevention Research Synthesis cumulative database of electronic and manual searches in MEDLINE, CINAHL, EMBASE, and PsycINFO from 2000 to 2019 to identify English-language primary studies reporting PrEP use. Two reviewers independently screened citations, extracted data, and assessed the risk of bias with the modified Newcastle-Ottawa Scale. We estimated pooled proportions and crude/adjusted odds ratio. RESULTS: We identified 95 eligible studies including 95,854 US-based survey respondents. A few studies (6.3%) focused on persons who inject drugs. In 2015-2017, men who have sex with men (MSM) had highest proportion of individuals who used PrEP over their lifetime [13.9% (95% confidence interval: 8.8 to 21.1), k (number of surveys) = 49] followed by Hispanic/Latinos [11.5 (7.1 to 18.1), 12], transgender women [11.2 (5.8 to 20.6), 5], and blacks [9.9 (8.3 to 11.8), 18]. Odds of PrEP use increased by 34%/year [odds ratio = 1.34/year (95% confidence interval: 1.09 to 1.64)] and significantly increased over time among MSM [1.53/year (1.21-1.93)] and blacks [1.44 (1.13-1.83)]. People in the Southern United States [9.9 (4.7-19.7), 8] and youth [7.3 (4.7-11.2), 8] had lower rates and did not demonstrate growth [0.94 (0.29-3.18); 0.82 (0.43-1.55)]. Odds of reporting lifetime PrEP use was twice [2.07 (1.27-3.38)] as great among MSM than non-MSM. CONCLUSIONS: Proportions of PrEP use in published surveys have been growing, but remain low for people in the Southern United States and youth, and understudied in persons who inject drugs. Limitations include few studies in certain years, whereas strengths include a large number of respondents. Culturally tailored approaches targeting vulnerable populations are essential in increasing PrEP use to reduce disparities in HIV acquisition.
BACKGROUND: Pre-exposure prophylaxis (PrEP) use among populations most vulnerable to HIV as identified in the national HIV prevention goals is not fully known. This systematic review assessed trends of lifetime self-reported PrEP use and disparities among key populations. METHODS: We used the CDC HIV/AIDS Prevention Research Synthesis cumulative database of electronic and manual searches in MEDLINE, CINAHL, EMBASE, and PsycINFO from 2000 to 2019 to identify English-language primary studies reporting PrEP use. Two reviewers independently screened citations, extracted data, and assessed the risk of bias with the modified Newcastle-Ottawa Scale. We estimated pooled proportions and crude/adjusted odds ratio. RESULTS: We identified 95 eligible studies including 95,854 US-based survey respondents. A few studies (6.3%) focused on persons who inject drugs. In 2015-2017, men who have sex with men (MSM) had highest proportion of individuals who used PrEP over their lifetime [13.9% (95% confidence interval: 8.8 to 21.1), k (number of surveys) = 49] followed by Hispanic/Latinos [11.5 (7.1 to 18.1), 12], transgender women [11.2 (5.8 to 20.6), 5], and blacks [9.9 (8.3 to 11.8), 18]. Odds of PrEP use increased by 34%/year [odds ratio = 1.34/year (95% confidence interval: 1.09 to 1.64)] and significantly increased over time among MSM [1.53/year (1.21-1.93)] and blacks [1.44 (1.13-1.83)]. People in the Southern United States [9.9 (4.7-19.7), 8] and youth [7.3 (4.7-11.2), 8] had lower rates and did not demonstrate growth [0.94 (0.29-3.18); 0.82 (0.43-1.55)]. Odds of reporting lifetime PrEP use was twice [2.07 (1.27-3.38)] as great among MSM than non-MSM. CONCLUSIONS: Proportions of PrEP use in published surveys have been growing, but remain low for people in the Southern United States and youth, and understudied in persons who inject drugs. Limitations include few studies in certain years, whereas strengths include a large number of respondents. Culturally tailored approaches targeting vulnerable populations are essential in increasing PrEP use to reduce disparities in HIV acquisition.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Tiara C Willie; Jamila K Stockman; Danya E Keene; Sarah K Calabrese; Kamila A Alexander; Trace S Kershaw Journal: J Acquir Immune Defic Syndr Date: 2019-04-01 Impact factor: 3.731
Authors: Lisa S Rotenstein; Marco A Ramos; Matthew Torre; J Bradley Segal; Michael J Peluso; Constance Guille; Srijan Sen; Douglas A Mata Journal: JAMA Date: 2016-12-06 Impact factor: 56.272
Authors: Albert Y Liu; Stephanie E Cohen; Eric Vittinghoff; Peter L Anderson; Susanne Doblecki-Lewis; Oliver Bacon; Wairimu Chege; Brian S Postle; Tim Matheson; K Rivet Amico; Teri Liegler; M Keith Rawlings; Nikole Trainor; Robert Wilder Blue; Yannine Estrada; Megan E Coleman; Gabriel Cardenas; Daniel J Feaster; Robert Grant; Susan S Philip; Richard Elion; Susan Buchbinder; Michael A Kolber Journal: JAMA Intern Med Date: 2016-01 Impact factor: 21.873
Authors: Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare Journal: Clin Infect Dis Date: 2015-09-01 Impact factor: 9.079
Authors: Emiko Kamitani; Adebukola H Johnson; Megan Wichser; Yuko Mizuno; Julia B DeLuca; Darrel H Higa Journal: BMJ Open Date: 2019-05-24 Impact factor: 2.692
Authors: Douglas A Mata; Marco A Ramos; Narinder Bansal; Rida Khan; Constance Guille; Emanuele Di Angelantonio; Srijan Sen Journal: JAMA Date: 2015-12-08 Impact factor: 56.272
Authors: Erik D Storholm; Daniel Siconolfi; Wenjing Huang; William Towner; Deborah Ling Grant; Alexander Martos; John M Chang; Rulin Hechter Journal: AIDS Behav Date: 2021-02-24
Authors: Dovie L Watson; Pamela A Shaw; Danielle T Petsis; Julia Pickel; José A Bauermeister; Ian Frank; Sarah M Wood; Robert Gross Journal: J Int AIDS Soc Date: 2022-02 Impact factor: 5.396
Authors: Valérie Martel-Laferrière; Daniel J Feaster; Lisa R Metsch; Bruce R Shackman; Christine Loignon; Bohdan Nosyk; Hansel Tookes; Czarina N Behrends; Nelson Arruda; Oluleye Adigun; Marie-Eve Goyer; Michael A Kolber; Jean-Francois Mary; Allan E Rodriguez; Iveth G Yanez; Yue Pan; Rania Khemiri; Lauren Gooden; Aïssata Sako; Julie Bruneau Journal: Trials Date: 2022-04-23 Impact factor: 2.728